Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00894101
Recruitment Status : Withdrawn (The main sponsor of this multi-center trial has submitted this protocol. A single participating site should not register this study.)
First Posted : May 6, 2009
Last Update Posted : April 4, 2011
Information provided by:
University of California, Irvine

Brief Summary:
The purpose of this study is to investigate the clinical value of serial quantitative [F-18] FLT as a PET imaging tool in head and neck cancer patients clinically scheduled with radiation or radiation-chemotherapy combination in terms of safety and efficacy. Standard [F-18] FDG PET will be the active comparator.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Drug: [F-18] FLT Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase II/III, Open Label, Non-Randomized, Multi-Center Study of Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation
Study Start Date : May 2009
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: [F-18] FLT and FDG Drug: [F-18] FLT
10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.

Primary Outcome Measures :
  1. The basic safety data of [F-18] FLT tracer will be collected. The treatment response evaluated based on the [F-18] FLT results will be compared to the response evaluated based on the standard PET trace [F-18] FDG. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient provides written Informed Consent and is willing to comply with protocol requirements
  2. Patient is at least 18 years of age on the day of dosing (male or female of any race or ethnicity)
  3. Patient is capable of lying still in the PET scanner for the protocol required time frame(s)
  4. Patient has a diagnosis of one of the following malignancies (TNM Staging System):

    • Lung cancer (T3 grade up, node positive, but no metastatic disease)
    • Head and neck cancer (T3 grade up, node positive, but no metastatic disease)
  5. Patient has undergone a comparative, diagnostic procedure with lesion(s) visible, other than ultrasound, that includes, but is not limited to computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine imaging, endoscopy, laparoscopy, standard abdominal x-ray, biopsy and/or surgery for one of the above mentioned areas
  6. Patient is scheduled to start radiotherapy or a chemoradiotherapy regimen for curative intent
  7. As a part of his/her standard radiotherapy or chemoradiotherapy regimen, patient is scheduled to have clinical [F-18] FDG PET scans pre treatment and post treatment (at about 4 weeks (±1 week) after the start of therapy)
  8. Patient is scheduled to have the investigational, pre treatment [F-18] FLT PET scan recommended to be within ± 2 days of the clinical, pre treatment [F-18] FDG PET scan
  9. Patient has not received or intends to receive 5-fluorouracil (5-FU-chemotherapeutic agent)
  10. Patient has a score of greater than or equal to (≥) 60% on the Karnofsky Performance Status Scale

Exclusion Criteria:

Exclude a patient from this study if the patient does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  1. Patient is a pregnant or lactating female. These methods will be used to exclude the possibility of pregnancy:

    • by testing on site at the institution (serum or urine βHCG) within 48 hours prior to the start of each investigational product administration,
    • by surgical history (eg, tubal ligation or hysterectomy),
    • by patient's history of being post menopausal with a minimum 1 year without menses.
  2. Patient is undergoing treatment with palliative intent
  3. Patient has received an investigational compound and/or medical device within 14 days before admission into this study
  4. Patient has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations
  5. Patient is determined by the Investigator that he/she is clinically unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00894101

United States, California
Department of Radiology, UCI Medical Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine

Responsible Party: Dr. Orhan Nalcioglu, Professor & Director, University of California, Irvine Identifier: NCT00894101     History of Changes
Other Study ID Numbers: HS# 2009-6857
First Posted: May 6, 2009    Key Record Dates
Last Update Posted: April 4, 2011
Last Verified: April 2011

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site